GlassScriptPhysician profile
Regina C Bowers
NPI 1467518589
$6,225.93
in general payments reported to CMS, 2019-2025
30 companies · $1,610 in 2025
The $1,610 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,152 · 2020: $325 · 2021: $453 · 2022: $453 · 2023: $1,022 · 2024: $1,211 · 2025: $1,610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,483 · Education: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,483.49 |
| Education | $359.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $691.96 | 2019-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $662.12 | 2019-2025 | |
| Janssen Biotech, INC. | $619.11 | 2020-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $596.17 | 2023-2025 | Zoryve |
| Abbvie INC. | $594.38 | 2019-2025 | Skyrizi |
| Lilly USA, LLC | $493.17 | 2019-2025 | Taltz, Ebglyss, Zepbound |
| Mayne Pharma Commercial LLC | $442.17 | 2019-2024 | |
| Almirall LLC | $284.40 | 2019-2025 | Klisyri, Seysara |
| Ucb, INC. | $252.91 | 2019-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $222.50 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $191.82 | 2019-2025 | |
| Botanix Sb INC | $168.26 | 2025 | Sofdra |
| Leo Pharma INC. | $124.94 | 2019-2025 | Adbry, Anzupgo |
| Incyte Corporation | $120.29 | 2023-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $108.48 | 2020-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $107.16 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $107.07 | 2024-2025 | Libtayo, Dupixent |
| Celgene Corporation | $97.59 | 2019 | |
| Epi Health, LLC | $52.82 | 2019-2021 | |
| Organon LLC | $45.85 | 2025 | Vtama |
| Dermavant Sciences, INC. | $39.82 | 2024 | Vtama |
| Verrica Pharmaceuticals INC. | $35.84 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $33.75 | 2019-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.95 | 2024 | Spevigo |
| Fresenius Kabi USA, LLC | $31.43 | 2023 | Idacio |
| Helsinn Therapeutics (U.S.), INC. | $15.56 | 2019 | |
| Biofrontera INC. | $15.20 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.47 | 2019 | |
| Mylan Pharmaceuticals INC. | $13.04 | 2019 | |
| Journey Medical Corporation | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Bowers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.